Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 23
2021 24
2022 13
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab.
Villaescusa L, Zaragozá F, Gayo-Abeleira I, Zaragozá C. Villaescusa L, et al. Adv Ther. 2022 Mar;39(3):1126-1148. doi: 10.1007/s12325-022-02042-3. Epub 2022 Jan 24. Adv Ther. 2022. PMID: 35072887 Free PMC article. Review.
Many of them are intended for the treatment of other pathologies; however, despite the great effort made, no specific drug is available for the treatment of the symptoms of respiratory disease caused by SARS-CoV-2 infection. The aim of this article is to prov …
Many of them are intended for the treatment of other pathologies; however, despite the great effort made, no specific drug is available for …
Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19.
Palanques-Pastor T, López-Briz E, Poveda Andrés JL. Palanques-Pastor T, et al. Eur J Hosp Pharm. 2020 Sep;27(5):297-298. doi: 10.1136/ejhpharm-2020-002322. Epub 2020 Jun 4. Eur J Hosp Pharm. 2020. PMID: 32499314 Free PMC article. Review.
The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug siltuximab in the management of severe forms of COVID-19. ...Siltuximab is a monoclonal antibody indicated in Ca …
The aim of the study was to explore the involvement of interleukin 6 in SARS-CoV-2 infection, and to position the drug …
Pharmaco-Immunomodulatory Therapy in COVID-19.
Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Rizk JG, et al. Drugs. 2020 Sep;80(13):1267-1292. doi: 10.1007/s40265-020-01367-z. Drugs. 2020. PMID: 32696108 Free PMC article. Review.
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of viral replication in concert with a host inflammatory response. ...In this review, we discuss the potential role and safety of these agents in …
The severe acute respiratory syndrome coronavirus 2 associated coronavirus disease 2019 (COVID-19) illness is a syndrome of vi …
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
Ghosn L, Assi R, Evrenoglou T, Buckley BS, Henschke N, Probyn K, Riveros C, Davidson M, Graña C, Bonnet H, Jarde A, Ávila C, Nejstgaard CH, Menon S, Ferrand G, Kapp P, Breuer C, Schmucker C, Sguassero Y, Nguyen TV, Devane D, Meerpohl JJ, Rada G, Hróbjartsson A, Grasselli G, Tovey D, Ravaud P, Chaimani A, Boutron I. Ghosn L, et al. Cochrane Database Syst Rev. 2023 Jun 1;6(6):CD013881. doi: 10.1002/14651858.CD013881.pub2. Cochrane Database Syst Rev. 2023. PMID: 37260086 Review.
BACKGROUND: It has been reported that people with COVID-19 and pre-existing autoantibodies against type I interferons are likely to develop an inflammatory cytokine storm responsible for severe respiratory symptoms. Since interleukin 6 (IL-6) is one of the cytokines …
BACKGROUND: It has been reported that people with COVID-19 and pre-existing autoantibodies against type I interferons are like …
Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, Jenkins G. Khan FA, et al. Thorax. 2021 Sep;76(9):907-919. doi: 10.1136/thoraxjnl-2020-215266. Epub 2021 Feb 12. Thorax. 2021. PMID: 33579777
BACKGROUND: There is accumulating evidence for an overly activated immune response in severe COVID-19, with several studies exploring the therapeutic role of immunomodulation. Through systematic review and meta-analysis, we assess the effectiveness of specific inter …
BACKGROUND: There is accumulating evidence for an overly activated immune response in severe COVID-19, with several studies ex …
COVID-19: Are Experimental Drugs a Cure or Cause?
Karahalil B, Elkama A. Karahalil B, et al. Curr Drug Saf. 2022;17(2):83-89. doi: 10.2174/1574886316666210727150127. Curr Drug Saf. 2022. PMID: 34315382 Review.
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a new strain of coronavirus. It is characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). ...At the beginning of the pandemic, death rates of infection caused by COVID …
BACKGROUND: Coronavirus disease 2019 (COVID-19) is a new strain of coronavirus. It is characterized by severe acute respirator …
Advances in clinical outcomes: What we have learned during the COVID-19 pandemic.
Al-Musa A, LaBere B, Habiballah S, Nguyen AA, Chou J. Al-Musa A, et al. J Allergy Clin Immunol. 2022 Feb;149(2):569-578. doi: 10.1016/j.jaci.2021.12.775. Epub 2021 Dec 24. J Allergy Clin Immunol. 2022. PMID: 34958811 Free PMC article. Review.
Because COVID-19 vaccines constitute the primary tool for ending this pandemic, strategies have been developed to address potential allergic and immune-mediated reactions. Here, we discuss advances in our understanding of COVID-19 risk factors and outc …
Because COVID-19 vaccines constitute the primary tool for ending this pandemic, strategies have been developed to address pote …
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach.
Aliyu M, Zohora FT, Anka AU, Ali K, Maleknia S, Saffarioun M, Azizi G. Aliyu M, et al. Int Immunopharmacol. 2022 Oct;111:109130. doi: 10.1016/j.intimp.2022.109130. Epub 2022 Aug 12. Int Immunopharmacol. 2022. PMID: 35969896 Review.
Recently, IL-6 secretion was shown to form the backbone of hypercytokinemia seen in the Coronavirus disease 2019 (COVID-19)-associated hyperinflammation and multiorgan failure. There are two classes of approved IL-6 inhibitors: anti-IL-6 receptor monoclonal antibodi …
Recently, IL-6 secretion was shown to form the backbone of hypercytokinemia seen in the Coronavirus disease 2019 (COVID-19)-as …
Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
Bedier H, Isnard S, Maedler-Kron C, Routy JP. Bedier H, et al. Eur J Case Rep Intern Med. 2023 Nov 17;10(12):004098. doi: 10.12890/2023_004098. eCollection 2023. Eur J Case Rep Intern Med. 2023. PMID: 38077710 Free PMC article.
On siltuximab, the patient developed two mild COVID-19 episodes. His response to siltuximab remained effective throughout four years. ...LEARNING POINTS: Lymph node biopsy rather than bone marrow biopsy is needed for the diagnosis of iMCD.We were able …
On siltuximab, the patient developed two mild COVID-19 episodes. His response to siltuximab remained effective t …
Experience with the use of siltuximab in patients with SARS-CoV-2 infection.
Meira F, Albiach L, Carbonell C, Martín-Oterino JA, Martín-Ordiales M, Linares L, Macaya I, Agüero D, Ambrosioni J, Bodro M, Cardozo C, Chumbita M, De la Mora M, García-Pouton N, Garcia-Vidal C, González-Cordón A, Hernández-Meneses M, Inciarte A, Laguno M, Leal L, Morata L, Puerta-Alcalde P, Rico V, Letona L, Cózar-Llistó A, Dueñas G, Solá M, Torres B, Rojas J, Moreno A, Moreno-García E, Torres M, Martínez JA, Soriano A, García F. Meira F, et al. Rev Esp Quimioter. 2021 Aug;34(4):337-341. doi: 10.37201/req/045.2021. Epub 2021 May 13. Rev Esp Quimioter. 2021. PMID: 33982984 Free PMC article.
OBJECTIVE: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that received siltuximab according to a protocol that aimed to early block the activity of IL-6 to avoid the progression of the inflammator …
OBJECTIVE: The study aims to describe characteristics and clinical outcome of patients with SARS-CoV-2 infection that r …
56 results